Replies to post #4691 on Pluristem Therapeutics Inc (PSTI)

[TC43]

I am not an expert but I have two guesses on this debate.

1) All the literature says that they are determining the dosage on large animals. After that,it says there will be another "pivotal trial" that will lead to fast commercial marketization. Maybe the final trial is a fast track that evaluates safety?

OR

2) If they are treating ARS, the safety concerns may take a back seat to the fact that a population will have a high death rate either way. Safety wouldn't matter if a person is probably dead anyway. I'd guess there is an exemption based on compassionate use.

[zzaatt]

So did the large animals tell the investigators if they had a headache? How about Pain? How about dizziness? Blurred Vision? I could go on- needless to say- they really can't communicate to scientists on their side effects.

It's important to remember the application of R18! We're talking
about individuals, who face a very high probability of death (after
exposure to radiation), and subjective reactions, such as blurred
vision will not be decisive.

I'm sure they did do a massive number of tests to see if any
significant biological indicators were negatively effected,
and they say, no, things are looking good.

My feeling is that due to the issues with N.Korea, the threat
of terrorists with dirty bombs, and the possibility of industrial
accidents, it would be the height of irresponsibility NOT to
have a good supply of R18 stashed away and ready to be
used. Waiting till 2019 to start building up a supply of R-18
and at the same time giving Pluristam the means to scale
up their production capabilities cannot wait (at least if I
was in charge!).

Safety studies can continue even as the responsible agencies
acquire a supply of the stuff, just in case...!

That would be my argument for pps relevant news much earlier
than 2019.